

Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

NCT07166315

Status RECRUITING
Sponsor Adelphi Real World
Enrollment 700 participants

Key Eligibility Criteria

Inclusion (3)

- Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
- Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
- Participant is aged 18 years or older at enrolment.

Exclusion (1)

- Participation in a clinical trial at enrolment.

Locations (1 total)

Royal National Hospital for Rheumatic Diseases, Bath, Somerset, United Kingdom